Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859.

被引：0

作者：

Rha, Sun Young

Lee, Jeeyun

Ryu, Min-Hee

Yin, Lina

Leconte, Pierre

Bhagia, Pooja

Oh, Do-Youn

机构：

[1] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol,Yonsei Canc Ctr, Seoul, South Korea

[2] Samsung Med Ctr, Seoul, South Korea

[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[4] Merck & Co Inc, Rahway, NJ USA

[5] MSD France, Puteaux La Defense, France

[6] Seoul Natl Univ, Coll Med, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.428

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：428 / 428

页数：1

共 50 条

[41] Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial. [J].

Pietrantonio, Filippo ;

Randon, Giovanni ;

Lonardi, Sara ;

Garattini, Silvio Ken ;

Tamberi, Stefano ;

Giommoni, Elisa ;

Di Donato, Samantha ;

Fornaro, Lorenzo ;

Brunetti, Oronzo ;

De Vita, Ferdinando ;

Frassineti, Giovanni Luca ;

Chini, Claudio ;

Spallanzani, Andrea ;

Bethaz, Valerie ;

Strippoli, Antonia ;

Latiano, Tiziana Pia ;

Cardellino, Giovanni Gerardo ;

Palermo, Federica ;

Miceli, Rosalba ;

Di Bartolomeo, Maria .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) :LBA4002-LBA4002

[42] First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial [J].

Shen, Lin ;

Zhang, Yanqiao ;

Li, Ziyu ;

Zhang, Xiaotian ;

Gao, Xiangyu ;

Liu, Bo ;

Wang, Yusheng ;

Ba, Yi ;

Li, Ning ;

Zhang, Ruixing ;

Zhang, Jingdong ;

Chen, Ye ;

Chen, Jian ;

Huang, Mingzhu ;

Fu, Yang ;

Liu, Mulin ;

Liu, Zheng ;

Zhao, Jun ;

Li, Wei ;

Wei, Jia ;

Li, Changzheng ;

Xu, Nong ;

Guo, Zengqing ;

Cao, Bangwei ;

Liu, Lian ;

Nie, Peng ;

Wan, Lixin ;

Sheng, Lili ;

Liu, Zhenyang ;

He, Yifu ;

Gu, Kangsheng ;

Wu, Guowu ;

Wang, Weibo ;

Zhang, Futong ;

Qiu, Wensheng ;

Guo, Jun ;

Ying, Jieer ;

Pan, Hongming ;

Xu, Huiting ;

Yuan, Yuan ;

Bai, Yuansong ;

Wang, Zhenghua ;

Xu, Jiye ;

Zhao, Xuehong ;

Liu, Hao ;

Zhang, Xizhi ;

Dai, Wenxiang ;

Xu, Hongyan ;

Liu, Ming ;

Xie, Lin .

NATURE MEDICINE, 2025, 31 (04) :1368-1368

[43] Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis [J].

Zheng, Zhiwei ;

Song, Xiaobing ;

Cai, Hongfu ;

Zhu, Huide .

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) :1017-1025

[44] Efficacy and side effects of pembrolizumab plus chemotherapy vs. chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A meta-analysis [J].

Li, Jinquan ;

Hu, Xiaosheng ;

Zhang, Shanzhong .

ONCOLOGY LETTERS, 2024, 28 (02)

[45] Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA). [J].

Catenacci, Daniel V. T. ;

Park, Haeseong ;

Lockhart, A. Craig ;

Gold, Philip Jordan ;

Enzinger, Peter C. ;

Nordstrom, Jeffrey L. ;

Hong, Sam ;

Hochster, Howard S. ;

Kelly, Ronan Joseph ;

Uronis, Hope Elizabeth ;

Bendell, Johanna C. ;

Oh, Sang Cheul ;

Park, Se Hoon ;

Kim, Yeul Hong ;

Kang, Yoon-Koo ;

Lee, Keun-Wook ;

Ng, Matthew C. H. ;

Wigginton, Jon M. ;

Davidson-Moncada, Jan Kenneth ;

Bang, Yung-Jue .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)

[46] Immune checkpoint inhibitor plus chemotherapy versus chemotherapy alone in HER2-negative advanced gastric or gastroesophageal junction cancer: A systematic review and meta-analysis of randomized controlled trials [J].

Oliveira, Joao Pedro ;

Mendes da Silva, Isadora Mamede ;

de Liz, Caio Dabbous ;

Maia, Melissa ;

Ferreira de Oliveira, Audrey Cabral ;

Fonseca Alves, Ana Caroline .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[47] KEYNOTE-062:Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. [J].

Tabernero, Josep ;

Bang, Yung-Jue ;

Fuchs, Charles S. ;

Ohtsu, Atsushi ;

Kher, Uma ;

Lam, Baohoang ;

Koshiji, Minori ;

Van Cutsem, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[48] Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study [J].

Xiang, Jinyu ;

Gong, Wenjing ;

Sun, Ping ;

Wang, Xuan ;

Liu, Aina .

JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (06) :2874-+

[49] Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma [J].

Janjigian, Y. Y. ;

Kawazoe, A. ;

Bai, Y. ;

Xu, J. ;

Lonardi, S. ;

Metges, J-P. ;

Weber, P. E. Yanez ;

Wyrwicz, L. S. ;

Shen, L. ;

Ostapenko, Y. V. ;

Bilici, M. ;

Chung, H. C. ;

Shitara, K. ;

Mahave, M. ;

Van Cutsem, E. ;

Tabernero, J. ;

Xu, L. ;

Sharan, K. ;

Bhagia, P. ;

Rha, S. Y. .

ANNALS OF ONCOLOGY, 2024, 35 :S877-S878

[50] Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study [J].